TNF and rheumatoid arthritis: In line with published literature, our analysis shows that the widespread adoption of TNF-alpha inhibitor biosimilars has been limited by the indication of these products to treat chronic conditions (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, etc.).